Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sanofi (SASY.PA) is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage of the delayed U.S. launch of competitor Novo Nordisk's (NOVOb.CO) new insulin.
The French drugmaker, which on Thursday reported first-quarter results, said it would provide a fresh timeline for the fixed-combination pen device, currently in mid-stage trials, next month.
Having a product that effectively combines two of its key diabetes treatments would bolster Sanofi's portfolio in a market that is becoming increasingly crowded despite the delayed arrival of a new insulin product by Novo Nordisk.
http://uk.reuters.com/article/2013/05/02/uk-sanofi-pipeline-idUKBRE9410IJ20130502
The French drugmaker, which on Thursday reported first-quarter results, said it would provide a fresh timeline for the fixed-combination pen device, currently in mid-stage trials, next month.
Having a product that effectively combines two of its key diabetes treatments would bolster Sanofi's portfolio in a market that is becoming increasingly crowded despite the delayed arrival of a new insulin product by Novo Nordisk.
http://uk.reuters.com/article/2013/05/02/uk-sanofi-pipeline-idUKBRE9410IJ20130502